CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Endpoints News
Original article

Roche aims to bolster breast cancer pipeline with early-stage Astex deal

Positive
AI Analysis

Summary

Roche's subsidiary Genentech acquired early-stage breast cancer assets from Otsuka's subsidiary Astex for an upfront fee of $25 million to strengthen its oncology pipeline.

Importance:6/10
Sentiment:
0.50
oncologybreast cancerM&ARocheAstexearly-stage
Related Companies

Read the original article

Published by Endpoints News on July 6, 2026 2:53 PM

Read Original